

Jonathan J Hogan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7587653/publications.pdf>

Version: 2024-02-01

54
papers

1,744
citations

430874

18
h-index

289244

40
g-index

54
all docs

54
docs citations

54
times ranked

2408
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	1.9	15
2	A Core Outcome Set for Trials in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 53-64.	4.5	4
3	Untangling immunotactoid glomerulopathy in the MGRS era. Kidney International, 2021, 99, 303-305.	5.2	3
4	Urinary Single-Cell Profiling Captures the Cellular Diversity of the Kidney. Journal of the American Society of Nephrology: JASN, 2021, 32, 614-627.	6.1	64
5	Kidney injury and disease in patients with haematological malignancies. Nature Reviews Nephrology, 2021, 17, 386-401.	9.6	20
6	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	1.7	3
7	A Case of Focal Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1272-1274.	4.5	0
8	The Role of Glomerular Epithelial Injury in Kidney Function Decline in Patients With Diabetic Kidney Disease in the TRIDENT Cohort. Kidney International Reports, 2021, 6, 1066-1080.	0.8	17
9	The Clone Wars: Diagnosing and Treating Dysproteinemic Kidney Disease in the Modern Era. Journal of Clinical Medicine, 2021, 10, 1633.	2.4	1
10	MO126CLINICAL AND BIOMARKER CHARACTERISTICS OF PATIENTS WITH C3G OR IC-MPGN ENROLLED IN TWO PHASE II STUDIES INVESTIGATING THE FACTOR D INHIBITOR DANICOPAN*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	2
11	Age and Racial Inequities in Telemedicine Internet Support Among Nephrology Outpatients During the COVID-19 Pandemic. Kidney Medicine, 2021, 3, 868-870.	2.0	2
12	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.	5.2	7
13	Towards optimizing use of PLA2R antibody testing in membranous nephropathy. Journal of Nephrology, 2021, 34, 557-559.	2.0	1
14	Recurrent Glomerular Disease after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1730-1742.	4.5	29
15	A focus group study of self-management in patients with glomerular disease.. Kidney International Reports, 2021, 7, 56-67.	0.8	2
16	Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. Kidney International, 2020, 97, 589-601.	5.2	32
17	Kidney Biopsy Is Required for Nephrotic Syndrome with PLA2R+ and Normal Kidney Function: Pro. Kidney360, 2020, 1, 887-889.	2.1	2
18	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 673-684.	4.5	66

#	ARTICLE	IF	CITATIONS
19	A Case of Nephrotic Syndrome after Allogeneic Stem Cell Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 873-875.	4.5	0
20	The Feasibility and Safety of Obtaining Research Kidney Biopsy Cores in Patients with Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1024-1026.	4.5	10
21	Case-based discussions in onco-nephrology. <i>Journal of Onco-Nephrology</i> , 2020, 4, 135-144.	0.6	1
22	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. <i>Kidney International Reports</i> , 2020, 5, 860-871.	0.8	2
23	Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 435-446.	6.1	247
24	Dysproteinemia and the Kidney: Core Curriculum 2019. <i>American Journal of Kidney Diseases</i> , 2019, 74, 822-836.	1.9	47
25	Lenalidomide-induced tubulointerstitial nephritis in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3084-3086.	1.3	2
26	Paraneoplastic Focal Segmental Glomerulosclerosis Associated With Acute Lymphocytic Leukemia. <i>Kidney International Reports</i> , 2019, 4, 1494-1498.	0.8	4
27	Standardized Outcomes in Nephrology-Related Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. <i>Kidney International</i> , 2019, 95, 1280-1283.	5.2	20
28	The Impact of Whole-Exome Sequencing on Kidney Disease Ontology: The Tip of the Iceberg?. <i>American Journal of Kidney Diseases</i> , 2019, 74, 281-283.	1.9	2
29	Native kidney BK virus nephropathy, a systematic review. <i>Transplant Infectious Disease</i> , 2019, 21, e13083.	1.7	16
30	A Case of ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 754-756.	4.5	0
31	Heavy Chain Fibrillary Glomerulonephritis: A Case Report. <i>American Journal of Kidney Diseases</i> , 2019, 74, 276-280.	1.9	16
32	The authors reply. <i>Kidney International</i> , 2019, 95, 468.	5.2	0
33	Hypertension in Cancer Patients and Survivors. <i>JACC: CardioOncology</i> , 2019, 1, 238-251.	4.0	68
34	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. <i>American Journal of Kidney Diseases</i> , 2019, 73, 218-229.	1.9	68
35	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	5.2	198
36	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	5.2	135

#	ARTICLE	IF	CITATIONS
37	Patient and Kidney Allograft Survival in Recipients With End-Stage Renal Disease From Amyloidosis. Transplantation, 2018, 102, 300-309.	1.0	15
38	Monoclonal Gammopathies and Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1781-1782.	4.5	2
39	DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. Journal of the American Society of Nephrology: JASN, 2018, 29, 2745-2754.	6.1	128
40	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.8	39
41	A Case of Monoclonal Gammopathy of Renal Significance. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 937-939.	4.5	1
42	Heme-pigment nephropathy after transurethral resection of prostate cancer. Journal of Onco-Nephrology, 2018, 2, 16-20.	0.6	1
43	A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney International, 2018, 94, 199-205.	5.2	90
44	New insights into the pathogenesis and treatment of heavy chain deposition disease. Kidney International, 2017, 91, 272-274.	5.2	4
45	Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection. Hepatology, 2017, 66, 658-660.	7.3	19
46	Quiz. American Journal of Kidney Diseases, 2017, 69, A10-A13.	1.9	1
47	Edema with hypoalbuminemia as a rare manifestation of chronic graft versus host disease after allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2017, 58, 2008-2010.	1.3	1
48	Cocaine Detection in Peritoneal Dialysis Fluid. American Journal of Kidney Diseases, 2017, 69, 161.	1.9	0
49	Atypical Antiglomerular Basement Membrane Disease With IgG1-Î² Staining. Kidney International Reports, 2017, 2, 80-83.	0.8	3
50	Chronic Lymphocytic Leukemia and the Kidney. Journal of Onco-Nephrology, 2017, 1, 103-109.	0.6	1
51	Hemophagocytic Syndrome With Histiocytic Glomerulopathy and Intraglomerular Hemophagocytosis. American Journal of Kidney Diseases, 2016, 67, 978-983.	1.9	20
52	The Native Kidney Biopsy. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 354-362.	4.5	205
53	Rituximab for treatment of severe renal disease in ANCA associated vasculitis. Journal of Nephrology, 2016, 29, 195-201.	2.0	33
54	Drug-Induced Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1300-1310.	4.5	75